Akari Therapeutics Overview

  • Founded

  • 2005

Founded
  • Status

  • Public

  • Employees

  • 15

Employees
  • Stock Symbol

  • AKTX

Stock Symbol
  • Investments

  • 1

  • Share Price

  • $0.16

  • (As of Friday Closing)

Akari Therapeutics General Information

Description

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.

Contact Information

Website
www.akaritx.com
Formerly Known As
Volution Immuno Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 75/76 Wimpole Street
  • London W1G 9RT
  • England, United Kingdom
+44 020 0000 0000

Akari Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akari Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.16 $0.16 $0.14 - $1.61 $16.2M 101M 569K -$0.28

Akari Therapeutics Financials Summary

In Thousands,
USD 		TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 26,832 26,832 58,005 58,858
Revenue 0 0 0 0
EBITDA (17,790) (17,790) (17,431) (17,086)
Net Income (17,748) (17,748) (17,424) (17,082)
Total Assets 13,832 13,832 11,648 14,605
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Akari Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Akari Therapeutics‘s full profile, request access.

Request a free trial

Akari Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Akari Therapeutics‘s full profile, request access.

Request a free trial

Akari Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute an
Drug Discovery
London, United Kingdom
15 As of 2022
00000
000000000 00000

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
Boulder, CO
000 As of 0000
00000
0000000000.

000 00

ris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Epalinges, Switzerland
000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akari Therapeutics Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clovis Oncology Formerly VC-backed Boulder, CO 000 00000 0000000000.
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
0000 00000000 Formerly VC-backed Boston, MA 000 00000 000000&0 00000
00000000 000000000 Formerly PE-Backed Suzhou, China 0000 00.000 000000000 00.000
0000000 Private Equity-Backed Prague, Czech Republic 0000 00.000 000000000 00.000
You’re viewing 5 of 63 competitors. Get the full list »

Akari Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Torsten Hombeck Ph.D Chief Financial Officer, Finance
Melissa Bradford-Klug Chief Operating Officer
Miles Nunn Chief Scientific Officer
Raymond Prudo-Chlebosz MD Executive Chairman
John Neylan MD Chief Medical Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Akari Therapeutics Board Members (11)

Name Representing Role Since
David Byrne Self Board Member 000 0000
Donald Williams Self Board Member 000 0000
Donald Williams Self Board Member 000 0000
James Hill Akari Therapeutics Board Member 000 0000
Michael Grissinger Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Akari Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akari Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Akari Therapeutics‘s full profile, request access.

Request a free trial

Akari Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 18-Sep-2015 0000000000 000.00 Biotechnology 000 00000
To view Akari Therapeutics’s complete acquisitions history, request access »